Insight
partnering360® also provides insightful content that gives executives a partnering edge. Tune in here to see high-profile panels, workshops, and interviews with leading dealmakers.
BIO-Europe Spring 2012
The opportunity of community drug development partnerships for personalized oncology and drug development
Mar 19, 2012
Will community drug development partnerships among academic institutions, diagnostics companies, technology providers and bio/pharma lead to more effective cancer drugs?
view full session here 
|
Biotech business models for faster returns
Mar 19, 2012
Nimble entrepreneurs are developing funds and corporate structures that may once again make private biotech an attractive investment, focusing on the drug, not the company.
|
view full session here
|
Are orphan indications the only viable model for drug development?
Mar 19, 2012
The opening plenary addresses orphan indications as a viable model for drug development. Panelists discuss development strategies and the future of personalized medicine.
|
view full session here
|
Regional focus: Leveraging commercial rights for emerging markets
Mar 19, 2012
Life science companies are shifting focus to take advantage of specialty indications and regional markets, such as China, the Middle East, Russia and South America
|
view full session here
|
Next generation anticancer approaches: Innovation meets commercial realities
Mar 20, 2012
This discussion focuses on how commercial realities meet innovation within oncology, covering challenges companies face as oncology becomes increasingly competitive.
|
view full session here
|
Close up and personal: Recent deals examined from both sides
Mar 19, 2012
With special emphasis on Dutch biotech deals, executives discuss what the dealmaking hurdles were, what they learned from the process, and how the alliance has been managed
|
view full session here
|
Unconventional deals to herculean strategies
Mar 19, 2012
New realities in healthcare have caused investors to lean toward non-traditional dealmaking strategies. Panelists explore multifaceted, powerful, even herculean, strategies.
|
view full session here
|
Advanced therapies: Stem cell and immunotherapy promises in practice
Mar 19, 2012
This panel examines major clinical and commercial developments in using stem cells as drug discovery platforms, as well as the development of immunotherapies to treat cancer.
|
view full session here
|
The assessment and management of assets: How to position the asset to attract a deal
Mar 20, 2012
There is still a great deal to learn about how to better position an asset to attract investors or deal partners, with an understanding of both short and long term goals.
|
view full session here
|
Early stage financing: European and US VCs weigh in
Mar 19, 2012
Is there a recipe for current VCs for successful investing in early stage science? Will recent initiatives from both government and industry help or hurt the venture industry?
|
view full session here
|
Examining major deals of the past year
Mar 19, 2012
Panelists examine significant deals of 2011, including what these deals reveal about pharma’s priorities, strategy and the options available to drug development companies.
|
view full session here
|
